Table 3.
Comparison of study design, populations, and outcomes for ceftaroline epidemiology studies
| Casapao et al. [7] | Zasowski et al. [8] | Britt et al. | |
|---|---|---|---|
| Sample size, n | 527 | 211 | 764 |
| Design | Retrospective | Retrospective | Retrospective |
| Setting | 5 hospitals | 3 hospitals | >150 hospitals |
| Geography | MI, OH, FL, IL | MI, FL | National |
| Population | Age (60 years) (median) Male (57.5%) Diabetes (40%) Hemodialysis (8%) Charlson score (2) (median) Antibiotics in prior 90d (30%) |
Age (59 years) (median) Male (56%) Diabetes (37%) Hemodialysis (21%) Charlson score (3) (median) |
Age (61 years) (median) Male (97%) Diabetes (56%) Hemodialysis (2%) Charlson score (6) (median) Antibiotics in prior 90d (87%) |
| Infections | Various infections | MRSA bloodstream infections | Various infections |
| Ceftaroline strategy | ≥72 hours of ceftaroline | ≥72 hours of ceftaroline | ≥1 dose of ceftaroline |
| Time to ceftaroline, median | 3 days | NR | 3 days |
| Clinical success, % | 88% | 68% | NR |
| Hospital LOS, median | 12 days | 12 days | 5 days |
| In-hospital mortality, % | 8% | 22% | 5% |
| 30-day hospital readmission, % | 9% | NR | 33% |
NR: not reported